EXICURE, INC. Restructuring Charges
EXICURE, INC. (XCUR) reported Restructuring Charges of $488.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-06-06.
Discontinued › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2024-06-06
- EXICURE, INC. restructuring charges for the quarter ending 2022-12-31 was $0.00.
- EXICURE, INC. restructuring charges for fiscal 2022 was $488.00K.
| Period end | Restructuring Charges 3 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|
| 2022-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2024-06-06 | $488.00K 10-K · filed 2024-06-06 | |
| 2022-09-30 | $488.00K 10-Q · filed 2022-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |